MANGOCEUTICALS, INC. COMMON STOCK

NASDAQ: MGRX (Mangoceuticals, Inc.)

最近更新时间: 4天之前, 10:56AM

2.62

0.05 (1.99%)

前收盘价格 2.57
收盘价格 2.59
成交量 128,872
平均成交量 (3个月) 174,373
市值 13,547,941
价格/销量 (P/S) 8.26
股市价格/股市净资产 (P/B) 0.950
52周波幅
1.49 (-43%) — 16.80 (540%)
营业利益率 (TTM) -2,264.62%
稀释每股收益 (EPS TTM) -4.84
季度收入增长率 (YOY) -56.90%
总债务/股东权益 (D/E MRQ) 1.54%
流动比率 (MRQ) 0.050
营业现金流 (OCF TTM) -4.86 M
杠杆自由现金流 (LFCF TTM) -1.09 M
资产报酬率 (ROA TTM) -62.72%
股东权益报酬率 (ROE TTM) -118.31%

市场趋势

短期 中期
行业 Health Information Services (US) 看跌 看跌
Health Information Services (全球的) 看跌 看跌
股票 Mangoceuticals, Inc. - -

AIStockmoo 评分

-1.3
分析师共识 -2.0
内部交易活动 1.5
价格波动 -2.0
技术平均移动指标 0.0
技术振荡指标 -4.0
平均 -1.30

相关股票

股票 市值 DY P/E(TTM) P/B
MGRX 14 M - - 0.950
SY 81 M 3.23% - 0.330
VSEE 19 M - - 3.95
BFRG 16 M - - 3.15
ACONW - - - -
VSEEW - - - -

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men’s wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

部门 Healthcare
行业 Health Information Services
内部持股比例 34.89%
机构持股比例 1.48%

所有权

姓名 日期 持有股份
Ackerman Capital Advisors, Llc 31 Dec 2024 34,500
Mccollum Christoferson Group Llc 31 Dec 2024 0

该时间范围内无数据。

该时间范围内无数据。

日期 类型 细节
25 Apr 2025 公告 ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector
25 Apr 2025 公告 Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division
22 Apr 2025 公告 CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape
25 Mar 2025 公告 Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada
20 Feb 2025 公告 Mangoceuticals Announces the Launch of “PeachesRx” - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments
12 Feb 2025 公告 Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution
06 Feb 2025 公告 Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research
03 Feb 2025 公告 Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票